Patents Assigned to Synedgen, Inc.
-
Patent number: 11957707Abstract: Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.Type: GrantFiled: September 17, 2019Date of Patent: April 16, 2024Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Stacy Marie Townsend
-
Patent number: 11911412Abstract: Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx.Type: GrantFiled: June 29, 2021Date of Patent: February 27, 2024Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann
-
Patent number: 11786547Abstract: Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.Type: GrantFiled: September 16, 2019Date of Patent: October 17, 2023Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Stacy Marie Townsend
-
Patent number: 11717532Abstract: Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.Type: GrantFiled: March 16, 2018Date of Patent: August 8, 2023Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Ruth Baxter
-
Patent number: 11433092Abstract: Described herein are a solution, composition, and kit of poly (acetyl, arginyl) glucosamine (PAAG), methods of making the solution, and method of treating wounds with the solution, the method comprising administering to a subject an effective amount of a solution comprising PAAG, wherein the PAAG when administered topically contacts the wound, thereby treating the wound.Type: GrantFiled: March 14, 2014Date of Patent: September 6, 2022Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Stacy M. Townsend
-
Patent number: 11077135Abstract: Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx.Type: GrantFiled: August 12, 2016Date of Patent: August 3, 2021Assignee: SYNEDGEN, INC.Inventors: Shenda Baker, William P. Wiesmann
-
Patent number: 10765616Abstract: Described herein are methods and compositions that contain a soluble polyglucosamine or polyglucosamine derivative for use in oral health. The compositions are useful for, e.g., reducing bacteria (e.g., by clumping and removing) or disrupting a biofilm in the mouth of a subject, reducing dry mouth, and reducing oral inflammation.Type: GrantFiled: April 9, 2018Date of Patent: September 8, 2020Assignee: SYNEDGEN, INC.Inventors: Stacy M. Townsend, Shenda M. Baker, William P. Wiesmann
-
Patent number: 10716803Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.Type: GrantFiled: June 13, 2018Date of Patent: July 21, 2020Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann
-
Patent number: 10494451Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.Type: GrantFiled: July 12, 2017Date of Patent: December 3, 2019Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann
-
Patent number: 10022393Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.Type: GrantFiled: September 20, 2013Date of Patent: July 17, 2018Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann
-
Publication number: 20170304355Abstract: Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.Type: ApplicationFiled: September 11, 2015Publication date: October 26, 2017Applicant: SYNEDGEN, INC.Inventors: Shenda Baker, William P. Wiesmann, Stacy Marie Townsend
-
Patent number: 9732164Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.Type: GrantFiled: April 10, 2015Date of Patent: August 15, 2017Assignee: SYNEDGEN, INC.Inventors: Shenda Baker, William P. Wiesmann
-
Patent number: 9439925Abstract: Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.Type: GrantFiled: April 6, 2011Date of Patent: September 13, 2016Assignee: SYNEDGEN, INC.Inventors: Shenda Baker, William P. Wiesmann, Ruth Baxter
-
Patent number: 9234050Abstract: Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal.Type: GrantFiled: March 12, 2013Date of Patent: January 12, 2016Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann
-
Publication number: 20150224044Abstract: Described herein is a method of reducing bacteria in the mouth of a subject, the method comprising contacting (e.g., rinsing) the mouth with an effective amount of a composition comprising a soluble derivatized chitosan, thereby reducing bacteria in the mouth of the subject.Type: ApplicationFiled: September 24, 2014Publication date: August 13, 2015Applicant: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Stacy Marie Townsend
-
Patent number: 9029351Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.Type: GrantFiled: January 13, 2014Date of Patent: May 12, 2015Assignee: Synedgen, Inc.Inventors: Shenda M. Baker, William P. Wiesmann
-
Patent number: 9012429Abstract: The present invention is directed to the treatment and prevention of nosocomial infections or MRSA infections utilizing soluble chitosan or chitosan derivative compounds. These chitosan-derivative compounds, e.g., chitosan-arginine and chitosan-acid amines, exhibit bactericidal activity against bacterial pathogens, e.g., drug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).Type: GrantFiled: August 14, 2009Date of Patent: April 21, 2015Assignee: Synedgen, Inc.Inventors: Shenda Baker, William P. Wiesmann
-
Patent number: 8916542Abstract: Described herein are methods and compositions using chitosan derivatives to treat and/or inhibit acquisition of multiple drug resistance (MDR). Also described herein are methods and compositions using chitosan derivatives in combination with an antibacterial agent to treat a bacterial infection and/or inhibit growth of bacteria, for example, resulting in a synergistic or sensitizing effect.Type: GrantFiled: November 12, 2009Date of Patent: December 23, 2014Assignee: Synedgen, Inc.Inventors: Shenda Baker, William P. Wiesmann, Stacy Townsend
-
Publication number: 20140301955Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.Type: ApplicationFiled: January 13, 2014Publication date: October 9, 2014Applicant: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann
-
Publication number: 20140221308Abstract: A method of treating a surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g., soluble or derivatized chitosan) with the surface, thereby treating the surface. Non-pharmaceutical compositions (e.g., liquid or dry powder compositions) include chitosan (e.g., a soluble or derivatized chitosan). The compounds and compositions described herein are biocompatible (e.g., non-toxic) and/or biodegradable (e.g., eco-friendly). Methods using the compositions described herein include methods of treating a surface (e.g., an inert and/or non-animal surface, e.g., a synthetic or semi-synthetic surface (e.g., cellulose, ceramic, plastic, metal, glass, wood, or stone); or a food or food product surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g.Type: ApplicationFiled: June 29, 2012Publication date: August 7, 2014Applicant: SYNEDGEN, INC.Inventors: Shenda Baker, William P. Wiesmann, Stacy M. Townsend